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Abstract 
 
     Antibiotics are becoming less effective as bacteria are acquiring resistance, so it is 
essential that new ones are discovered. An example of a multidrug-resistant bacterial 
strain is methicillin-resistant Staphylococcus aureus (MRSA), which has infected around 
95,000 patients and caused 19,000 deaths per year in the United States alone. 
Streptomyces are soil bacteria that have been the source of many antibiotics and 
therapeutics. In order to potentially discover a novel antibiotic to treat resistant bacteria 
like MRSA, a Streptomyces was isolated from soil and determined to be Streptomyces 
violaceorectus based on its 16S rRNA gene sequence. S. violaceorectus produces an 
antibiotic that inhibits the growth of Gram-positive and Gram-negative bacteria. With the 
recent lack in antibiotic discovery, new treatment options are necessary to combat 
antibiotic resistance. Combination antibiotic therapy, the simultaneous use of multiple 
antibiotics, has become a successful clinical treatment, especially with the use of a 
beta-lactam antibiotic such as ampicillin.  
     This project helped determine the difference in inhibitory effect of the antibiotic 
produced by S. violaceorectus when used alone and in combination with ampicillin 
against MRSA. The antibiotic combination was more effective at inhibiting the growth of 
MRSA, and this difference was significant and replicable over 15 trials. Further analyses 
will increase our knowledge of the antibiotic produced by S. violaceorectus and its ability 
to inhibit resistant bacteria by itself or in combination with another antibiotic for future 
medical use. 
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Chapter 1: Literature Review 
 
1.1: The History of Antibiotics 
 
1.1.1: The Discovery of Penicillin 
 
 Sir Alexander Fleming was born in 1881 into a farming family in Scotland (1). 
During his childhood, Fleming’s father died, which forced him and his siblings to 
determine their future career paths (1). He began work as an office clerk, but later 
switched to the field of medicine and joined the department of bacteriology at St. Mary’s 
Hospital in London, England (1). Before leaving for a month-long vacation in the midst 
of his career, he set aside Petri dishes containing bacterial colonies of Staphylococcus 
(1). When he returned from his leave, Fleming noticed that one of his dishes was 
contaminated with a mold that had inhibited the growth of Staphylococcus (2) (Figure 1-
1). After taking samples of the mold, he conducted a series of experiments to determine 
the nature of its ability to inhibit bacteria. Fleming later identified the mold as Penicillium 
and named the inhibitory substance that it secreted penicillin (2). This accidental finding 
of his in 1928 eventually resulted in the discovery of the first true antibiotic, penicillin (3). 
 Bacterial infections that are easily treatable today were once a major cause of 
death. Before 1928, there were minimal treatment options for infected patients (1). This 
is a problem that Fleming wished to solve. Following the introduction of penicillin, he 
aimed to demonstrate if it could be used in human medicine. He began by performing 
experiments on animals, but at the time, most researchers were only using its 
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antimicrobial capabilities as a tool for isolating Bacillus influenzae (1). A few years later, 
Howard Florey and Ernst Chain were able to purify penicillin from cultures of Fleming’s 
mold (3). This pure form of penicillin was manufactured and put to use during World 
War II as a treatment for soldiers with infectious diseases (1). Fleming, Florey, and 
Chain were later awarded with the Nobel Prize in Physiology or Medicine in 1945 for the 
significance of their discoveries in the field of microbiology (3).  
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Figure 1-1 
 
Figure 1-1. Inhibition of Staphylococci colonies due to Penicillium. A bacterial 
culture-plate displaying the dissolution of Staphylococci colonies in the presence of the 
fungi, Penicillium. Adapted from (2). 
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1.1.2: The Different Classes of Antibiotics 
 
 With the purification and identification of additional antibiotics, several systems 
were established in order to classify them. Most classification systems have organized 
antibiotics according to their molecular structures, mechanisms of action, and 
antimicrobial activity (4). There are multiple classes of antibiotics, and the following 
provides a brief description of the majority of them (Figure 1-2): 
• Beta-lactams are antibiotics that contain a four-member ring moiety comprised of 
3 carbons and 1 nitrogen (4) (a beta-lactam ring). The beta-lactam class is 
composed of four distinct antibiotic classes: Penicillins, Cephalosporins, 
Carbapenems, and Monobactams (5). These compounds interfere with 
peptidoglycan synthesis in the bacterial cell wall, which can lead to cell 
lysis/death (6). They do so by binding to penicillin-binding proteins (PBP), which 
are bacterial enzymes that assist in the formation of peptidoglycan (5). PBPs are 
primarily involved in the transglycosylation and cross-linking processes of 
peptidoglycan synthesis (7).  
• Penicillins are beta-lactam antibiotics that contain a 6-animopenicillanic acid ring 
in their structure (4). Most of these compounds disrupt the synthesis of bacterial 
cell walls and have the suffix ‘–cillin’ in their names (4). The Penicillin class 
includes antibiotics such as penicillin, amoxicillin, ampicillin, methicillin, and 
others (8).  
• Cephalosporins are beta-lactam antibiotics that are similar to the penicillins in 
regards to their structure and mechanism of action. However, these compounds 
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contain a 7-animocephalosporanic acid ring in their structure (4). The 
Cephalosporin class includes antibiotics such as cephalexin, cefroxadine, 
cefadroxil, and others (9).  
• Carbapenems are beta-lactam antibiotics that are frequently employed for 
patients infected with antibiotic-resistant bacteria (4). These compounds are able 
to resist beta-lactamases, enzymes that hydrolyze the beta-lactam ring of some 
antibiotics, due to the steric hindrance induced by the carbon atom at the C-1 
position (10). They also inhibit the activity of beta-lactamases because of the 
trans configuration at the C-5 and C-6 position of their beta-lactam ring (10). The 
Carbapenems class includes antibiotics such as doripenem, imipenem, 
meropenem, and others (10).  
• Monobactams are beta-lactam antibiotics with a structure that contains a beta-
lactam ring that is not combined with another ring (4). The beta-lactam ring in 
these compounds stands alone. This structural variance allows for the 
attachment of different functional groups to the molecule and can inhibit the 
activity of beta-lactamases (11). The only available antibiotic in the Monobactam 
class is aztreonam, which was synthetically modified to enhance the activity of 
the beta-lactam ring when attempting to bind to its targets (11).  
• Quinolones are antibiotics that inhibit bacterial DNA replication and transcription 
(4). These compounds generally have the suffix ‘–oxacin’ in their names, and 
some modifications have been added to them to improve their antimicrobial 
potency (4). For example, a third ring added to their structure (4) or a halogen 
added to the 8-position of their fused rings enhances their activity against certain 
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anaerobic bacteria (12). The Quinolone class includes antibiotics such as 
norfloxacin, ofloxacin, cinoxacin, and others (12).  
• Macrolides are antibiotics that contain a macrocyclic lactone ring in their structure 
that consists of 14-16 members (13). These compounds inhibit protein synthesis 
by binding to bacterial ribosomes and disrupting the formation of polypeptide 
chains (14). The Macrolide class includes antibiotics such as azithromycin, 
erythromycin, clarithromycin, and others (4).  
• Tetracyclines are antibiotics that contain four hydrocarbon rings in their structure 
and have the suffix ‘–cycline’ in their names (4). These compounds target the 
bacterial ribosome and disrupt protein synthesis (15). The Tetracycline class 
includes antibiotics such as tetracycline, oxytetracycine, chlortetracycline, and 
others (15).  
• Sulphonamides are antibiotics that contain a sulfonamide group in their structure 
(16). At high concentrations, these compounds can kill bacteria (16). Otherwise, 
they prevent bacterial growth and reproduction. The Sulphonamide class 
includes antibiotics such as sulfacetamide, sulfadiazine, sulfamethoxazole, and 
others (17).  
• Glycopeptides are antibiotics with a structure that contains a cyclic peptide core 
of seven amino acids that are bound to two amino sugars (18). The peptidic 
backbone of these compounds forms 5 hydrogen bonds when attaching to its 
target (19). The Glycopeptide class includes antibiotics such as vancomycin, 
teicoplanin, oritavancin, and others (18).  
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• Aminoglycosides are antibiotics with a structure that contains multiple glycosidic 
bonds that connect 3-amino sugars (20). These compounds disrupt bacterial 
protein synthesis by attaching to the A-site of ribosomal subunits and disturbing 
ribosomal translocation (21). The Aminoglycoside class includes antibiotics such 
as streptomycin, neomycin, gentamicin, tobramycin, and others (22). 
• Oxazolidinones are synthetic antibiotics that contain 2-oxazolidone in their 
structure (23). These compounds interfere with protein synthesis by binding to 
the peptidyl transferase center of ribosomes (24). The Oxazolidinone class 
includes antibiotics such as linezolid, tedizolid, and others currently in clinical 
development (24).  
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Figure 1-2 
A.            B.       C.                D. 
 
E.             F.       G. 
 
H.              I.     J. 
 
K.        L. 
 
	 12	
Figure 1-2. General structure of various antibiotic classes. A. Beta-lactam ring. B. 
Penicillins. D. Carbapenems. C. Cephalosporins. E. Monobactams. F. Quinolones. G. 
Macrolides. H. Tetracyclines. I. Sulphonamides. J. Glycopeptides. K. Aminoglycosides. 
L. Oxazolidinones. Structures adapted from (25, 26, 26, 10, 27, 28, 29, 30, 16, 18, 20, 
23), respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 13	
1.1.3: The Mechanisms of Action of Antibiotics 
 
 The different classes of antibiotics can affect bacteria through various 
mechanisms of action that occur inside a cell. These include the inhibition of bacterial 
protein synthesis, nucleic acid synthesis, and cell wall synthesis (4). Additionally, 
antibiotics can cause cell membrane breakdown in bacteria and can negatively affect 
bacterial metabolism by blocking fundamental metabolic pathways (4). These drugs 
generally target bacterial properties that are not present in or very different than 
eukaryotes, thus preventing harm to the host. Because of their mechanisms of action, 
the use of antibiotics commonly results in the termination of bacterial cell growth, and 
frequently cell death.  
 The bacterial ribosome, a molecular structure involved in protein synthesis, 
contains a 30S subunit and a 50S subunit that are comprised of rRNA and proteins (31). 
Together, these structures translate mRNA into amino acids through the initiation, 
elongation, and termination stages (31). The A-site on the 30S subunit is involved in 
codon-anticodon recognition, the peptidyl transferase center forms peptide bonds 
between adjacent amino acids that are attached to their corresponding tRNAs, and the 
exit tunnel on the 50S subunit allows the newly made peptide to leave the ribosome 
(31). Certain antibiotics, such as Aminoglycosides, bind to the A-site, prevent codon 
recognition, and interfere with translation (32). Oxazolidinones are compounds that bind 
to the peptidyl transferase center and inhibit the formation of peptide bonds (31). 
Macrolides are an example of an antibiotic that can disrupt protein synthesis by binding 
to and blocking the exit tunnel on the 50S ribosomal subunit to prevent protein growth 
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(31). These processes, carried out by several classes of antibiotics, lead to the 
termination of bacterial protein synthesis. 
 Nucleic acid synthesis is the process that produces new strands of bacterial DNA 
and RNA. DNA is synthesized through DNA replication, and RNA is synthesized 
through transcription. During both of these reactions, two key enzymes, topoisomerase 
II and topoisomerase IV, regulate DNA coiling (33). Their function is to overwind and 
underwind DNA strands to prevent them from breaking under the large amounts of 
tension created by helicases (33). Many antibiotics, such as Quinolones, bind to DNA-
topoisomerase complexes and prevent the rejoining of the DNA or RNA strands (33). 
This results in the termination of nucleic acid synthesis. Other compounds can prevent 
the continuation of transcription by binding to and obstructing RNA polymerase, the 
enzyme that is involved in the formation of new RNA strands (32). Additionally, an 
antibiotic has been determined to inhibit the activity of DNA polymerase, the enzyme 
that is involved in the formation of new DNA strands (32). Regardless of their 
mechanism of action, the disruption of nucleic acid synthesis adversely affects bacterial 
cells.  
 The bacterial cell wall is an important structure that provides a cell with shape 
and resistance to various types of stress (5). It is comprised of a cross-linking network 
of peptidoglycan, a compound formed from the attachment of short peptides to N-
acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) (5). The glycosidic and 
peptide bonds that form this large network of molecules are catalyzed with the 
assistance of penicillin-binding proteins (5). Most antibiotics that inhibit the synthesis of 
bacterial cell walls are Beta-lactams, and they do so by interacting with the active site of 
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penicillin-binding proteins (5). This prevents the formation of cross-links between 
peptidoglycan molecules, which eventually results in cell death. Other than Beta-
lactams, the Glycopeptide antibiotic, vancomycin, has been determined to prevent the 
attachment of short peptides to NAM (34). Likewise, this mechanism of action can 
detrimentally affect bacterial cells. 
 The bacterial cell membrane acts like a barrier that selectively allows the 
passage of specific molecules in and out of a cell (35). It also has certain properties that 
make it an attractive target for many antibiotics. Cell membranes are primarily 
composed of phospholipids, but bacterial cell membranes have negatively charged 
lipids exposed on their surface (35). Cationic antibiotics can be used to bind to these 
anionic lipids to disrupt the clustering and curvature of the phospholipids (35). 
Compounds that affect these membrane properties can be toxic to bacteria. For 
example, Polymyxins are positively charged antibiotics that bind to lipopolysaccharide, a 
negatively charged component of the bacterial membrane (36). When this occurs, the 
outer layers of the cell destabilize, resulting in its death (36). 
 In addition to the mechanisms of action discussed, it has been determined that 
some antibiotics mimic specific molecules that are needed for key metabolic pathways 
(4). This would result in enzymes binding to these antibiotics instead of their proper 
substrates, causing various sorts of metabolic problems. For example, Sulphonamides 
mimic tetrahydrofolate, a compound required by bacterial cells for the synthesis of folic 
acid (4). Whether bacterial metabolism is negatively affected, nucleic acid or protein 
synthesis is inhibited, or the formation of the outer layers of cells is disrupted, antibiotics 
severely damage, and often kill, bacteria.  
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1.2: Antibiotic Resistance 
 
1.2.1: The Rise of Antibiotic Resistance 
 
 The discovery of antibiotics has revolutionized the field of medicine and impacted 
healthcare across the globe. They have helped decrease the mortality rates of various 
regions, while ensuring the successful treatment of bacterial infections in patients (37). 
However, the efficacy of antibiotics has been shown to decrease over time due to the 
development of resistance in pathogenic bacteria, which occurs when bacteria acquire 
other genes or mutations that give them a competitive advantage in environments 
where there is selective pressure from antibiotic use (37). Multidrug-resistance occurs 
when bacteria acquire resistance to multiple classes of antibiotics, usually from the use 
of broad-spectrum antibiotics (38). Additionally, the multidrug-resistant capacity of 
numerous bacterial strains has spread through the processes of cross-infection and 
horizontal gene transfer (38). This has become a challenge for many countries and has 
resulted in higher morbidity rates worldwide (38). In order to combat the increasing rates 
of emergence of multidrug-resistant bacteria, new solutions are needed. 
 With the lack of clinical interventions available for patients infected with 
multidrug-resistant bacteria, the discovery of new antibiotics has appeared to be a 
plausible solution. However, it has been difficult to find compounds that can penetrate 
the bacterial cell membrane without being toxic to human cells (39). Another challenge 
has been generating antibiotics that are more successful than the current options used 
to treat infectious diseases (39). The production and development of candidate drugs is 
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also a long and costly process, so it may be at the best interest of the public health for 
business strategies to focus on minimizing the time and money needed for the 
implementation of clinical trials (39). 
 The “antibiotic resistance crisis” has become more problematic with the recent 
rise of multidrug-resistant bacteria and lack of antibiotic discovery. This has led to the 
introduction of multiple antibiotic development programs in the pharmaceutical industry 
(40). Given that it takes time for clinical trials to take place, some of the focus has 
shifted towards the prevention of the diffusion of multidrug-resistance pathogens and 
the improvement of the limited antimicrobial therapies that are currently being employed 
(37). Furthermore, new approaches to targeting bacterial infections can only be 
produced if the mechanisms of resistance and molecular pathways of antibiotic-resistant 
bacteria are fully understood (40).  
 
1.2.2: Mechanisms of Resistance 
 
 When interacting with antibiotics, bacteria have been found to use various 
mechanisms of resistance to prevent any damage to their cell. These pathways are the 
result of intrinsic resistance or acquired resistance (41). Bacteria can be intrinsically 
resistant to different classes of antibiotics because of an inherent structural or functional 
property that obstructs the antibiotic’s mechanism of action (41). This is the reason why 
a specific antibiotic is not effective against all species of bacteria. Extrinsic resistance to 
antibiotics can develop in three ways: the prevention of access into the cell, the 
modification of antibiotic targets, and the inactivation of antibiotics (41). Acquired 
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resistance occurs as a result of mutations in bacterial genes or through the process of 
horizontal gene transfer (42). 
 In order to prevent an antibiotic from entering a bacterial cell, the bacterium can 
either reduce its membrane permeability or increase its efflux (41). The cell membrane 
is composed of multiple protein channels that permit the passage of different 
substances. These include porins and other non-selective channels, which allow for the 
passive diffusion of many particles, and selective channels, which allow for the diffusion 
of only specific particles (41). Bacteria can down-regulate the expression of non-
selective protein channels and up-regulate the expression of more selective ones, thus 
restricting antibiotics from entering the cell (41). This can act as a cell’s first line of 
defense against an antibiotic.  
 In addition to changing their cell membrane permeability, bacteria can increase 
the transport of antibiotics outside of the cell through the action of efflux pumps. Efflux 
pumps are active transporters on the cell membrane that move substances to the 
extracellular environment (42). Some of these molecular structures can transport a 
small range of substrates, while others, termed multidrug efflux pumps, can lead to the 
passage of a wide range of compounds out of the cell (43). Although all bacteria have 
genes that code for multidrug efflux pumps, they are only highly expressed in multidrug-
resistant bacteria (41). Not only do they act on a variety of antibiotics because of their 
poly-substrate specificity, multidrug efflux pumps lower the intracellular concentration of 
antibiotics (43). Without antibiotics entering the cell, multidrug-resistant bacteria have a 
greater opportunity to acquire mutations that will confer additional resistance to other 
antibiotics. 
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 Most antibiotics bind with high affinity to their intracellular targets (41). Bacteria 
have adapted to this by altering the target’s molecular structure in such a way that still 
allows it to function normally (41). With a change in the structure of its target, an 
antibiotic cannot bind effectively. This usually occurs with the introduction of a mutation 
in the gene that codes for the target, which spreads throughout the bacterial population 
through recombination (41). Bacteria have also developed protective mechanisms to 
prevent efficient antibiotic binding. For example, Aminoglycoside antibiotics are inhibited 
from binding to their target, the ribosome, if it is methylated (41). Additionally, some 
intracellular compounds have been discovered to promote the release of an antibiotic 
from an antibiotic-target complex (41). Even though the antibiotic might have entered 
the cell in either case, it will not be able to exert its effects because it cannot properly 
bind to its target. 
 It has also been determined that bacteria can block the action of antibiotics by 
degrading or modifying them (42). There are thousands of bacterial enzymes that can 
destroy foreign compounds through the process of hydrolysis. For example, the use of 
penicillin led to the discovery a penicillinase, a beta-lactamase (42). Beta-lactamases 
are hydrolytic enzymes expressed in bacteria that degrade beta-lactam antibiotics (10). 
Likewise, there are compounds known as extended-spectrum beta-lactamases, which 
can act on all classes of beta-lactam antibiotics (42). Additionally, bacterial enzymes 
can add chemical groups, such as phosphate, acyl, and nucleotidyl groups, to an 
antimicrobial substance (41). This ensures that the modified antibiotic will be sterically 
hindered from binding to its target.  
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 Whether bacteria acquire resistance or are intrinsically resistant to antibiotics, 
there is a diverse array of mechanisms that can confer antibiotic resistance. It is 
possible that more are discovered as new approaches are utilized to treat infectious 
diseases in patients. 
 
1.2.3: How Antibiotic Resistance Spreads 
 
 When a bacterium acquires a mutation in a gene that confers antibiotic 
resistance, it will have a better chance of survival than susceptible bacteria in an 
environment with antibiotics (42). In a population of bacteria, this antibiotic-resistant 
mutant will predominate and reproduce while antibiotic-susceptible bacteria die.  
 Bacteria can also obtain genetic material from methods other than reproduction, 
such as through horizontal gene transfer (44). This includes the processes of 
transformation, transduction, and conjugation (42). Transformation occurs when 
bacteria directly uptake foreign DNA or a replicable plasmid from their surrounding 
environment and integrate it into their genome (45). Transduction occurs when 
bacteriophages infect a bacterial cell and introduce foreign DNA into its genome (41). 
Conjugation occurs when a cell-to-cell junction is formed between two bacterial cells, 
and one of them transfers some of its DNA to the other (42). Most often, mobile genetic 
elements, such as transposons and plasmids, are replicated and then transported into 
the conjugated cell (42). The genetic material that is passed between bacteria as a 
result of horizontal gene transfer can contain genes that confer antibiotic resistance. 
When this is the case, as it is often, antibiotic resistance spreads.  
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1.2.4: Methicillin-Resistant Staphylococcus aureus  
 
 Staphylococcus aureus is a facultative aerobic strain of Gram-positive bacteria 
that has infected humans and animals for centuries (7). As opportunistic pathogens, 
they most commonly infect soft tissue, the skin, and the respiratory system (7). S. 
aureus also naturally colonizes and lives in various parts of the human body (7). When 
penicillin was first introduced in the 1940s, it became the first antimicrobial substance 
that was effective against S. aureus (1). Only one year later, penicillin-resistant S. 
aureus evolved and was found to contain a plasmid with the beta-lactamase gene, blaZ, 
which conferred antibiotic resistance (7). In 1959, methicillin, a derivative of penicillin, 
was used to successfully treat patients infected with penicillin-resistant S. aureus (7). 
Similarly, methicillin-resistant S. aureus (MRSA) evolved two years later (7). Since then, 
MRSA has continued to be a significant problem to the public health of regions across 
the globe, severely impacting their morbidity and mortality rates (46). New treatment 
options for patients infected with these difficult-to-treat multidrug-resistant bacteria must 
be found. 
 The cell wall of MRSA has a thick layer of peptidoglycan, which is cross-linked in 
a reaction catalyzed by various penicillin-binding proteins (PBPs) (7). Most PBPs have 
two domains, one involved in transglycosylation and one involved in the cross-linking 
process (7). Methicillin and other beta-lactam antibiotics bind to and inhibit the cross-
linking domain of PBPs, thus disrupting the formation of peptidoglycan in S. aureus and 
killing the cell (5). However, MRSA has evolved the use of a different PBP, PBP2a, 
which has a reduced affinity for beta-lactam antibiotics (46). The mecA gene encodes 
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PBP2a, and therefore, confers resistance to beta-lactam antibiotics, including methicillin 
(7). The mobile chromosomal cassettes in MRSA known as Staphylococcal 
chromosomal cassettes mecA (SCCmecA) contain the mecA gene (46). It has been 
hypothesized that the mecA gene was acquired through horizontal gene transfer from a 
different species of Staphylococcus (46). 
 Strains of MRSA have been differentiated into two broad groups: hospital-
acquired MRSA (HA-MRSA) and community-acquired MRSA (CA-MRSA) (47). These 
pathogenic forms are genetically and epidemiologically distinct (47). Initially, MRSA 
infections would emerge as HA-MRSA in major hospitals and healthcare systems, 
where they are now considered endemic (47). The pathogen would spread through 
contact between patients, physicians, and other individuals working those 
environments. But in the 1990s, CA-MRSA clones that differed from HA-MRSA were 
found in healthy people in the community who had no prior healthcare exposure (46). 
Although both forms of MRSA are resistant to beta-lactam antibiotics, they are treated 
differently. Variations in treatment also depend on the location, severity, and type of 
infection (47). For example, CA-MRSA strains are most commonly treated with 
vancomycin, tetracycline, and clindamycin (7). HA-MRSA strains are also susceptible to 
vancomycin, but can effectively be treated with daptomycin and linezolid too (7). 
However, the difference between HA-MRSA and CA-MRSA is being blurred, as they are 
both rapidly acquiring resistance to the same antibiotics (47). 
 The incidence of MRSA infections has increased worldwide, and its range of 
distribution is estimated to be between 23% and 73% (7). In the United States, the 
prevalence of MRSA has also been increasing, from 2% in 1974 to 64% in 2004 (7). It 
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has been determined that MRSA infects about 95,000 patients and causes 19,000 
deaths per year in the U.S. alone (46). There are many factors that can assist in the 
transmission of this pathogen, such as a compromised immune system (47). Likewise, 
crowded environments, skin-to-skin contact, lack of cleanliness, and contamination can 
also influence MRSA’s highly virulent path (47). The spread of MRSA is a public hazard 
that needs to end, especially since treatment options for infected patients are 
diminishing as these bacteria are rapidly evolving resistance to additional antibiotics. 
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1.3: Streptomyces 
 
1.3.1: Selman Waksman  
 
 Selman Abraham Waksman was born in Novaya Priluka, Ukraine towards the 
end of the 19th century (48). As a child, he became very interested in the fertile soil that 
surrounded his hometown. He later migrated to the United States and attended Rutgers 
College, where he studied soil bacteria (48). Specifically, Waksman focused on 
actinomycetes, which are Gram-positive, facultative anaerobic bacteria (48). After 
noticing how actinomycetes multiply and kill common bacteria also living in the soil, he 
began to consider the possibility of antibiotic production (49). 
 Waksman and his research team were persistent in their studies of 
actinomycetes, resulting in the discovery of four new antibiotics: actinomycin, fumigacin, 
streptothricin, and clavacin (49). Unfortunately, tests indicated that the antibiotics 
displayed toxicity in animals (49). Waksman continued to search for more antibiotic-
producing soil bacteria, and in 1943, he isolated a species of bacteria that resembled 
Actinomyces griseus (49). However, unlike previous A. griseus isolates, this new isolate 
produced an antibiotic (49). Waksman termed the new antibiotic, streptomycin, and the 
new species of bacteria, Streptomyces griseus (49). This resulted in the creation of a 
new genus of actinomycete bacteria, Streptomyces. 
 Streptomycin was found to be the first antibiotic that effectively cured 
tuberculosis, significantly impacting the field of medicine (49). Waksman also 
successfully received a patent for the antibiotic and helped develop a fermentation 
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method for its mass production (48). He became known as the “Father of Antibiotics” 
and was awarded with the Nobel Prize in Physiology or Medicine in 1952 (48). Notably, 
Waksman revolutionized the field of microbiology with his discovery of the Streptomyces 
genus. 
 
1.3.2: Streptomyces: A Possible Solution to Antibiotic Resistance 
  
 Streptomyces are Gram-positive, filamentous bacteria that generally inhabit soil 
and are involved in the decomposition of organic matter (50). As phylogenetically part of 
the Actinobacteria phylum, their DNA is GC-rich (50). To survive stressors or extreme 
environments, some species of Streptomyces can produce exospores. In favorable 
conditions, spores germinate to form hyphae, a structure commonly found in fungi but 
rare among most Gram-positive bacteria (50). Together, hyphae filaments arrange into 
interlinking networks known as mycelium. Streptomyces are also known to produce 
secondary metabolites such as antifungals and antibiotics, which has made them an 
important focus of study in the treatment of bacterial infections (50). The most studied 
species of Streptomyces are Streptomyces griseus, for the production of streptomycin, 
and Streptomyces coelicolor, for genetic analyses (50).  
 Streptomyces are abundant and adaptable bacteria with high rates of secondary 
metabolite production. Antibiotic production is species specific throughout the entire 
genus, and antibiotic secretion enables Streptomyces to compete with other 
microorganisms living in the surrounding soil (50). Antibiotics are also beneficial to 
plants by protecting them from harmful bacteria, creating a symbiotic relationship 
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between certain species of Streptomyces and plants living in the same environment 
(50). Furthermore, the genetic sequencing of these bacteria can be used to indicate the 
genetic basis and purpose of their antibiotic production. 
 Streptomyces have produced 80% of the antibiotics that are currently identified, 
many of which are utilized in clinical practice (50). These antibiotics, such as 
streptomycin, tetracycline, vancomycin, and daptomycin, can be and have been used to 
combat multidrug-resistant bacteria (50). However, with the recent lack in antibiotic 
discovery, infectious diseases continue to be one of the leading causes of death 
globally (50). As bacterial infections remain the cause of millions of deaths, the search 
for new antibiotics is essential. Nonetheless, Streptomyces might be the source of a 
solution to this ongoing crisis. 
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1.4: Combination Antibiotic Therapy  
 
1.4.1: The Positive/Negative Effects of Combination Antibiotic Therapy 
 
 With the recent rise of multidrug-resistant bacterial infections, the necessity for 
new treatment options for patients is vital. One such possibility that has been employed 
is combination antibiotic therapy, a treatment that involves prescribing multiple 
antibiotics to be taken simultaneously (51). Combination antibiotic therapy is a highly 
selective process, but it frequently consists of the use of a beta-lactam antibiotic with an 
aminoglycoside antibiotic (51). Whether this creates more or less success for infected 
patients has become a subject of debate, particularly because combination antibiotic 
therapy has been determined to only work in certain cases. However, the advantages 
and disadvantages of combination antibiotic therapy can assist in deciding the best 
situations for its utilization.  
 One of the main reasons for the usage of combination antibiotic therapy is to 
create synergistic drug interactions (51). Synergistic combinations of antibiotics can kill 
multidrug-resistant infections more effectively than antibiotics that are taken individually 
(51). For example, it was determined that the combination of Stephania suberosa 
Forman extract and ampicillin displays synergy at inhibiting the growth of ampicillin-
resistant Staphylococcus aureus (52). It was also determined that the combination of a 
bioactive fraction from Duabanga grandiflora and ampicillin displays synergy at 
inhibiting the growth of MRSA (53). Additionally, the combination of tigecycline and 
carbapenem has been used to effectively treat patients with carbapenemase-containing 
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Klebsiella pneumonia infections (51), and the combination of ceftazidime and 
tobramycin has been proven to be an effective treatment for cystic fibrosis patients 
infected with Pseudomonas aeruginosa (54). Antibiotic combinations broaden the 
antimicrobial spectrum, ensuring that at least one antibiotic will be successful at treating 
the infected patient. This can work especially well on polymicrobial infections, diseases 
that contain multiple bacterial pathogens (51). Likewise, combination antibiotic therapy 
can help prevent the emergence of bacterial resistance by forcing bacteria to acquire 
mutations that confer resistance to more than just one antibiotic in order to survive (51). 
This does not occur as often as singular drug resistance, which is why combination 
antibiotic therapy may be advantageous. 
 However, combination antibiotic therapy is a costly treatment that may put 
patients at risk for adverse side effects. Unlike synergistic drug interactions, certain 
combinations might display antagonism, where one antibiotic can either nullify or 
weaken the effects of the other on bacteria (54). When this occurs, the antibiotic 
combination will be less effective at treating patients than if each antibiotic was used 
individually. For example, it was determined that the combination of ceftazidime and 
ciprofloxacin was less effective at inhibiting the growth of Pseudomonas aeruginosa 
than when each was used alone (55). The potency of antagonism depends on the 
situation, but the worst-case scenario would be the development of a superinfection 
(54). Combinations of antibiotics frequently cannot kill every bacterial cell, because 
certain cells will acquire mutations that enable them to survive in an antimicrobial 
environment. Concurrently, other nearby bacteria might also develop resistance and 
could potentially add to the previous infection. This creates what is known as a 
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superinfection, where different pathogens that are resistant to the antibiotics infect the 
same patient (54). In order to prevent these unfavorable consequences of combination 
antibiotic therapy, physicians should ensure that its benefits outweigh the costs on a 
circumstantial basis. 
 
1.4.2: Drug Interactions 
 
 There has recently been a lag in the discovery of antibiotics and great difficulty in 
selecting effective drug combinations. As the treatment options for patients with 
bacterial infections shifts more towards combination antibiotic therapy, so does the 
study of drug interactions. It is important to consider how different antibiotics will react 
with one another to find the most successful antibiotic combinations. Antibiotics can 
interact in an additive, synergistic, antagonistic, or suppressive manner (56). Additive 
drug combinations are just as effective at inhibiting bacterial growth as the sum of each 
antibiotic when used alone (56). In comparison to additive combinations, synergistic 
combinations are more effective and antagonistic combinations are less effective (56). 
Suppression is simply an extreme version of antagonism where an antibiotic 
combination is less effective against bacteria than the use of just one of the antibiotics 
(56).  
 Current research has focused on discovering synergistic antibiotic combinations, 
and approaches such as the chequerboard technique (57) and INDIGO (INferring Drug 
Interactions using chemo-Genomics and Orthology) (58) have assisted in doing so. 
Chequerboards and time-kill curves are used to set fractional inhibitory concentration 
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indices for determining synergy or antagonism amongst antibiotic combinations (57). 
This method can be helpful by comparing new data with already published results. 
INDIGO also predicts effective drug interactions, but consists of an algorithm that uses 
chemogenomics to systematically screen for antibiotic combinations (58). When 
experimentally tested, INDIGO was able to identify synergistic and antagonistic drug 
combinations that are effective against Escherichia coli and Staphylococcus aureus 
(58). The data has suggested that antagonistic combinations are more prevalent than 
synergistic combinations (58). Furthermore, drug interactions vary in their effectiveness 
against different bacteria.  
 
1.4.3: Antibiotic Stewardship 
 
 Antibiotic stewardship refers to the proposed interventions that are aimed at 
improving the appropriate use of antibiotics and selecting for the ideal drug dosage, 
duration, and administration (59). The Infectious Diseases Society of America, the 
Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of 
America have defined this as the pathway to superior patient care and reduced risk of 
adverse side effects from antibiotic utilization (59). Many hospitals have incorporated an 
antibiotic stewardship program as a guideline for physicians who are prescribing 
antibiotics to their patients (40). For example, it is recommended that alternative dosing 
strategies are used over broad-spectrum beta-lactam antibiotics, physicians increase 
the appropriate use of and transition to oral antibiotics, antibiotic therapies are reduced 
to the shortest duration of time, and antibiotic cycling is not performed (59). Antibiotic 
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stewardship programs should be implemented in all accredited healthcare facilities and 
need to adapt to the local environments of their patient base. With more people 
receiving an evidence-based education on antibiotic usage, healthcare systems can find 
cost-effective strategies to prevent the emergence of antibiotic resistance in infected 
patients. 
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Chapter 2: Research Manuscript 
 
2.1: Introduction  
 
 Since the discovery of penicillin by Alexander Fleming in 1928 (1), antibiotics 
have become an important solution to various medical complications. For example, 
bacterial infections that previously resulted in millions of deaths can now be cured with a 
simple, prescribed medication. However, as antibiotic use increased, the emergence of 
antibiotic-resistant bacteria also increased (38). Resistance is acquired with the 
accumulation of genes that confer resistance through specific agents, multidrug efflux 
pumps, and other factors (60). This rise in antibiotic-resistant bacterial infections has 
decreased the efficacy of antibiotics currently used to treat infected patients, which has 
proven to be detrimental to the overall health of society (61). An example of a multidrug-
resistant bacterial strain is methicillin-resistant Staphylococcus aureus (MRSA), which 
are Gram-positive bacteria that have infected approximately 95,000 patients and 
caused 19,000 deaths per year in the United States alone (46). The incidence of MRSA 
infections has increased worldwide, and its range of distribution is estimated to be 
between 23% and 73%, thus creating a hazard to the public health (7). 
 As treatment options are diminishing, it is essential that new antibiotics are 
discovered. Unfortunately, the search for new antibiotics has been impeded because of 
the high costs associated with testing the success of new drugs (61). A genus of Gram-
positive bacteria, Streptomyces, could end this antibiotic resistance crisis. Streptomyces 
were discovered by Selman Waksman in 1943 and are primarily found in soil (49). They 
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produce diverse secondary metabolites that have historically been a source of 
antibiotics and antifungals (50). Additionally, Streptomyces have produced 80% of the 
antibiotics currently used in clinical practice (50). Streptomyces violaceorectus is a 
Gram-positive bacterium isolated from the University of Texas at Austin that is able to 
produce an antimicrobial substance that is effective against Gram-positive bacteria, 
Gram-negative bacteria, and fungi (62). The strength of its effect on each varies, with it 
being the most effective against Gram-positive bacteria (62). The antibiotic produced by 
S. violaceorectus resembles endomycin, an antibiotic used in medical treatment, so it 
could have future applications in human medicine (62). 
 Combination antibiotic therapy is a common practice in which multiple antibiotics 
are prescribed together for simultaneous use to treat a bacterial infection (63). This is 
significant because the combined effect of the antibiotics can overcome the resistance 
of bacteria to a single antibiotic (63). Antibiotics in combination can target different 
essential processes of a bacterium, such as preventing protein synthesis or destroying 
cell walls, which can eventually lead to cell death (4). Combination antibiotic therapy 
with a beta-lactam antibiotic, such as ampicillin, is commonly used as a clinical 
treatment for patients dealing with resistant bacterial infections (64). 
 Little is known about the antibiotic produced by S. violaceorectus, and it is 
important to understand how it interacts when combined with ampicillin against 
antibiotic-resistant bacteria. The experiments described in this manuscript tested the 
effectiveness of combination antibiotic therapy using the antibiotic produced by S. 
violaceorectus and ampicillin against MRSA. Specifically, I measured the difference in 
inhibitory effect of the antibiotic produced by S. violaceorectus when used alone and in 
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combination with ampicillin on MRSA. I also measured the difference in inhibitory effect 
of the antibiotic produced by S. violaceorectus when used alone and in combination with 
ampicillin on methicillin-sensitive Staphylococcus aureus (MSSA) to control for the 
difference between MRSA and MSSA. Results indicated that the antibiotic combination 
was significantly more effective at inhibiting the growth of both MRSA and MSSA. 
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2.2: Methods 
 
2.2.1: Strains, Media, and Growth Conditions 
 
 Tryptic Soy Broth Yeast Extract (TSB-YE) agar (30 g tryptic soy broth, 5 g yeast 
extract, 20 g agar, and 1 L nanopure water) was used for the growth of S. 
violaceorectus. TSB-YE agar was also used for the growth of MRSA and MSSA during 
all disc assay experiments. MRSA LAC-CI3 and MSSA HG003-CI48 strains were 
obtained from Dr. Marvin Whiteley. All agar plates were grown at room temperature for 
at least four days. S. violaceorectus colonies were grown in 25 mL of TSB-YE media for 
four days in a 30° C shaking incubator to be used for ethyl acetate extraction.  
 
2.2.2: Bacterial Strain Isolation and Identification 
 
 Soil samples were collected at the University of Texas at Austin and plated on 
Actinomycete Isolation agar (20 mL 50% glycerol, 2.5 g L-arginine, 1 g NaCl, 0.1 g 
CaCO3, 10 mg FeSO4 - 7H2O, 10 mg MgSO4 – 7H2O, 20 g agar, 200 mg cyclohexamide 
in EtOH, and 1 L nanopure water). Bacteria were isolated from Actinomycete Isolation 
agar and plated on TSB-YE agar for growth. The 16S rRNA gene of strains was 
amplified through polymerase chain reaction using universal 16S primers (forward – 
AGAGTTTGATCCTGGCTCAG and reverse – ACTACCAGGGTATTAATCC) and the 
Thermo Taq polymerase system. PCR products were sequenced at the University of 
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Texas Institute for Cell and Molecular Biology DNA core facility. Strains were identified 
through Basic Local Alignment Search Tool (BLAST) analysis.  
 
2.2.3: Ethyl acetate Extractions 
 
 20 mL of S. violaceorectus cultures were mixed with an equal volume of ethyl 
acetate, vortexed for 60 seconds, and allowed to phase separate. Once separated, the 
organic layer was removed and this process was repeated. The extracts were 
evaporated to dryness under a constant stream of nitrogen gas. Extracts were then re-
suspended in 200 µL of methanol. All extracts were combined into a single glass vial to 
create uniformity for disc assays. 
 
2.2.4: Disc Assays 
 
 A lawn of MRSA (or MSSA) was spread on a TSB-YE agar plate. A paper disc 
was saturated in the extract of S. violaceorectus and dried for 60 seconds. Once dry, it 
was placed on the bacterial lawn. This procedure was repeated using methanol (instead 
of the extract of S. violaceorectus) to act as a control. To display combination antibiotic 
therapy, the same procedure was repeated using the extract of S. violaceorectus, 
except 2 µL of 100 µg/mL ampicillin (dissolved in water) were added to the disc after it 
was placed on the lawn. To control for ampicillin, a disc was placed on the lawn and 2 
µL of 100 µg/mL ampicillin were added to it. The diameters of the zones of inhibition on 
disc assays were measured after one week of growth to test the inhibitory effect of the 
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antibiotic produced by S. violaceorectus under different conditions (larger zones 
represented greater inhibition). They were used to measure the difference in inhibitory 
effect of the antibiotic produced by S. violaceorectus when used alone and in 
combination with ampicillin on MRSA. They were also used to measure the difference in 
inhibitory effect of the antibiotic produced by S. violaceorectus when used alone and in 
combination with ampicillin on MSSA to control for the difference between MRSA and 
MSSA. Disc assays were replicated for 15 trials, and the results were analyzed with a 
two-sample t-test. 
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2.3: Results & Discussion 
 
2.3.1: Isolation of Bacteria 
 
 In order to potentially discover new antibiotic-producing bacteria, a strain of 
Streptomyces was isolated from soil at the University of Texas at Austin and its 16S 
rRNA gene was amplified and sequenced. BLAST analysis determined its closest 
relative to be Streptomyces violaceorectus (Figure 2-1A). S. violaceorectus produces 
an antimicrobial substance that inhibits the growth of Gram-positive bacteria, Gram-
negative bacteria, and fungi (62). Streptomyces have produced many of the antibiotics 
used in clinical practice (50), so there is a possibility that this unknown compound could 
have future applications in human medicine. 
 There remains a necessity for the discovery of new antibiotics and new treatment 
options for patients coping with antibiotic-resistant infections because of the ongoing 
antibiotic resistance crisis. With minimal research on S. violaceorectus, any information 
regarding the antibiotic that it produces could be pertinent to the medical field.  
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Figure 2-1 
A.                                                                      
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B.  
 
Figure 2-1. Characterization of an antibiotic-producing Streptomycete. An 
antibiotic-producing Streptomycete was isolated from soil on the University of Texas at 
Austin campus. Its 16S rRNA gene was sequenced and BLAST analysis suggested S. 
violaceorectus to be the most closely related strain. A. Pairwise sequence alignment of 
isolate (top sequence) and S. violaceorectus (bottom sequence). B. The ability of an 
extract of S. violaceorectus to inhibit the growth of MRSA and MSSA was demonstrated 
by zones of inhibition. The symbol “I” represents a bacterial lawn of MRSA, and the 
symbol “II” represents a bacterial lawn of MSSA. The symbol “C” represents the 
methanol control. 
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2.3.2: Organic Extractions 
  
 In order to isolate the antibiotic produced by S. violaceorectus, organic 
extractions of S. violaceorectus cultures were performed. During the growth of bacterial 
cultures, many cells secrete compounds such as antimicrobials and antifungals. 
Organic extractions are necessary to remove impurities and contaminants. Multiple 
extracts of S. violaceorectus were prepared and combined together. This created 
uniformity and controlled for the variance between different extractions. S. 
violaceorectus extracts were used to test their inhibitory effect on MSSA and MRSA 
through combination antibiotic therapy with ampicillin.  
  
2.3.3: Inhibition of MSSA and MRSA 
 
 In order to determine if S. violaceorectus extracts have antimicrobial properties, a 
disc assay was performed to demonstrate that the extract from S. violaceorectus 
cultures inhibits the growth of both MSSA and MRSA (Figure 2-1B). Although MRSA 
exhibits resistance to multiple antibiotics, this result confirms the effectiveness of S. 
violaceorectus extracts at inhibiting its growth. With MRSA infecting hundreds of 
thousands of individuals worldwide (46), new methods need to be developed to end its 
nature as a hazard to the public health. The success of the antibiotic produced by S. 
violaceorectus against MRSA makes it a promising candidate for the pharmaceutical 
industry as a potential clinical drug. 
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 A separate disc assay was performed to represent the inhibitory effects of 
combination antibiotic therapy on MRSA and MSSA (Figure 2-2). It demonstrates that 
the antibiotic produced by S. violaceorectus also inhibits the growth of both MSSA and 
MRSA when combined with ampicillin. This finding is critical because new treatment 
options are needed for patients who have multidrug-resistant bacterial infections. One 
such treatment is combination antibiotic therapy. The results from this disc assay prove 
that the antibiotic produced by S. violaceorectus is a promising candidate for this type of 
treatment. Additionally, combination antibiotic therapy with S. violaceorectus extracts 
might display superiority to currently used antibiotic combinations, which would be 
beneficial to patients dealing with difficult-to-kill bacterial infections. 
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Figure 2-2 
 
Figure 2-2. Representative disc assay. Disc assay to represent all factors of the 
experiment. The symbol “I” represents a bacterial lawn of MRSA, and demonstrated is 
the ability of an extract of S. violaceorectus to inhibit the growth of MRSA. The symbol 
“II” represents a bacterial lawn of MRSA, and demonstrated is the ability of the 
combination of an extract of S. violaceorectus and ampicillin to inhibit the growth of 
MRSA. The symbol “III” represents a bacterial lawn of MSSA, and demonstrated is the 
ability of an extract of S. violaceorectus to inhibit the growth of MSSA. The symbol “IV” 
represents a bacterial lawn of MSSA, and demonstrated is the ability of the combination 
of an extract of S. violaceorectus and ampicillin to inhibit the growth of MSSA. The 
symbol “C” represents the methanol control, and the symbol “CA” represents the 
ampicillin control. Note that the ampicillin control inhibits the growth of MSSA and not 
MRSA, indicating that MRSA is resistant to ampicillin. 
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2.3.4: Inhibitory effect of the antibiotic produced by S. violaceorectus when used 
alone vs. in combination with ampicillin on MRSA 
 
 In order to determine if the diameters of the zones of inhibition on disc assays 
were larger when the antibiotic produced by S. violaceorectus was used in combination 
with ampicillin than when used alone on MRSA, a two-sample t-test using the diameters 
from 15 disc assays was performed (Figure 2-3). This result was significant with a p-
value less than 0.00001 and demonstrates that the antibiotic combination had a greater 
inhibitory effect on MRSA. Similar results were obtained when the antibiotic produced 
by S. violaceorectus was used in combination with ampicillin against MSSA (Figure 2-
4). The addition of ampicillin to the antibiotic produced by S. violaceorectus increased 
the diameters of zones of inhibition, despite MRSA’s resistance to ampicillin. This 
finding is consistent with the explanation that the antibiotics acted synergistically when 
used simultaneously (56). It is possible that the interaction between the antibiotics 
weakened the resistance of MRSA to the beta-lactam antibiotic class. Further research 
might determine that the antibiotic produced by S. violaceorectus displays superior 
synergistic drug interactions with other antibiotics. 
 The mechanism of action of the antibiotic produced by S. violaceorectus might 
have also negatively affected one or more mechanisms of resistance in MRSA. This 
would explain the increase in susceptibility of MRSA to ampicillin. For example, 
membrane permeability could have increased, drug efflux could have decreased, or 
bacterial enzymes could have been inhibited. Therefore, the antibiotic should be of 
interest to pharmaceutical companies because of its potential to be used in medical 
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practice as a treatment for infected patients. New discoveries such as those from this 
study appear promising in the current antibiotic resistance crisis.  
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Figure 2-3 
A. 
 
B. 
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C. 
 
Figure 2-3. Combination antibiotic therapy of antibiotics on MRSA. Disc assays 
compared the difference in inhibitory effect of the antibiotic produced by S. 
violaceorectus when used alone and in combination with ampicillin on MRSA. A. 
Representative disc assays to test for the ability of the antibiotic produced by S. 
violaceorectus to inhibit the growth of MRSA. The symbol “C” represents the methanol 
control. B. Representative disc assays to test for the ability of the combination of 
ampicillin and the antibiotic produced by S. violaceorectus to inhibit the growth of 
MRSA. The symbol “C” represents the methanol control, and the symbol “CA” 
represents the ampicillin control. C. Measurements of the diameter of the zone of 
inhibition on 15 disc assays. The antibiotics in combination were more potent against 
MRSA than the use of only the antibiotic produced by S. violaceorectus. This result was 
significant with a p-value less than 0.00001. 
	 48	
Figure 2-4 
A. 
 
B. 
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C. 
 
Figure 2-4. Combination antibiotic therapy of antibiotics on MSSA. Disc assays 
compared the difference in inhibitory effect of the antibiotic produced by S. 
violaceorectus when used alone and in combination with ampicillin on MSSA. A. 
Representative disc assays to test for the ability of the antibiotic produced by S. 
violaceorectus to inhibit the growth of MSSA. The symbol “C” represents the methanol 
control. B. Representative disc assays to test for the ability of the combination of 
ampicillin and the antibiotic produced by S. violaceorectus to inhibit the growth of 
MSSA. The symbol “C” represents the methanol control, and the symbol “CA” 
represents the ampicillin control.  C. Measurements of the diameter of the zone of 
inhibition on 15 disc assays. The antibiotics in combination were more potent against 
MSSA than the use of only the antibiotic produced by S. violaceorectus. This result was 
significant with a p-value less than 0.00001. 
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2.4: Limitations 
 
 Although the experiments demonstrated that the antibiotic produced by S. 
violaceorectus is more effective against MRSA when combined with ampicillin than 
when used alone, the structure and mechanism of action of the antibiotic remains 
unknown. It could be an antibiotic that has been studied before, possibly one that is 
currently used as a medical treatment. Without knowledge of the molecular nature of the 
antibiotic, its mechanism of action against MRSA is difficult to determine. This would 
have narrowed down the possibilities as to the reasons why the synergistic effects with 
ampicillin were observed. Additionally, the antibiotic produced by S. violaceorectus was 
used only once on any given lawn of MRSA. If there was repeated use, the likelihood of 
MRSA acquiring resistance to it over time exists and is highly probable. Slight variations 
in the amount of antibiotic distributed on each disc assay also could have affected the 
results because the discs were simply dipped into a solution of S. violaceorectus 
extract. To address these issues, further tests need to purify and identify the compound 
(or compounds) present in S. violaceorectus extracts that inhibits the growth of MRSA. 
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2.5: Future Directions 
 
 As the antibiotic resistance crisis continues, it is essential that antibiotic 
stewardship programs are implemented and new antibiotics are discovered. However, 
the emergence of novel drugs has declined (61). Many antibiotics are currently in 
clinical development, whether natural products or chemical derivatives of natural 
products, but have not been proven to be completely effective against various 
multidrug-resistant bacterial infections (65). Therefore, the mechanisms of resistance in 
bacteria must be studied before pharmaceutical companies can demonstrate the 
efficacy of new drugs. Once understood, existing antibiotics can be chemically modified 
to help target and combat distinct pathways of resistance (65). For example, species-
specific antibiotics can be generated, which would prevent many of the adverse effects 
of using broad-spectrum antibiotics (66). Additionally, different screening techniques 
can be employed to search for organisms that produce new antibiotics or possibly new 
antibiotic classes. Technological advances can explore microbial diversity or utilize 
hypersensitive approaches to detect antimicrobial agents (65). Novel computational 
methods to screen for antibiotic synergism, such as INDIGO, can also improve the 
success of combination antibiotic therapy (58). With the discovery of additional 
synergistic antibiotic combinations, treatment options for patients will expand and the 
public health hazard of multidrug-resistant bacterial infections will diminish. 
 Streptomyces are a current focus of study because of their potential to produce 
antimicrobial substances (50). For example, transposon mutagenesis has been utilized 
to transport DNA sequences from antibiotic-producing Streptomyces into other 
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Streptomyces species (67). The transposons generally contain genes for antibiotic 
production or genes that will up-regulate the biosynthesis of antibiotics (67). This 
process of transposon mutagenesis can be assisted by the complete genome 
sequencing of different Streptomyces species. With genomic data, the metabolic 
pathways of antibiotic biosynthesis can be constructed and the genes involved in 
antibiotic production can be identified (68). Additionally, new bacterial growth strategies, 
such as co-culturing, can induce antibiotic production in Streptomyces (69). Bacteria 
produce antibiotics in response to their environment in order to protect themselves from 
natural enemies (4). Thus, the environmental stress that results from culturing multiple 
bacterial species together can enhance the production of various compounds. 
Therefore, the future of antibiotic discovery could begin with understanding antibiotic 
production in Streptomyces.   
 The antibiotic produced by S. violaceorectus has demonstrated its potential to be 
used as a medical treatment for antibiotic-resistant bacterial infections. However, it must 
first be purified and identified before any further tests are conducted to help determine 
whether it is a new antibiotic or one that has already been discovered. If novel, then its 
molecular structure and mechanism of action against MRSA should be studied to 
determine its effectiveness against different bacterial pathogens. This would also create 
opportunities for the identification of the pathways in which the antibiotic produced by S. 
violaceorectus can enhance the activity of other antibiotics through combination 
antibiotic therapy. For example, it should be studied with the INDIGO computational 
approach (58). Using chemogenomics data, synergistic antibiotic combinations would 
be predicted and the efficacy of combination antibiotic therapy with the antibiotic 
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produced by S. violaceorectus can be improved. Afterwards and with successful results, 
there is a possibility for its implementation in clinical trials.  
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